[go: up one dir, main page]

EP1103234B1 - Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz - Google Patents

Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz Download PDF

Info

Publication number
EP1103234B1
EP1103234B1 EP99830721A EP99830721A EP1103234B1 EP 1103234 B1 EP1103234 B1 EP 1103234B1 EP 99830721 A EP99830721 A EP 99830721A EP 99830721 A EP99830721 A EP 99830721A EP 1103234 B1 EP1103234 B1 EP 1103234B1
Authority
EP
European Patent Office
Prior art keywords
envelope
stent
process according
radioactive
exerting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99830721A
Other languages
English (en)
French (fr)
Other versions
EP1103234A1 (de
Inventor
Franco Vallana
Benito Chinaglia
Maria Curcio
Giovanni Rolando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorin Biomedica Cardio SpA
Original Assignee
Sorin Biomedica Cardio SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorin Biomedica Cardio SpA filed Critical Sorin Biomedica Cardio SpA
Priority to AT99830721T priority Critical patent/ATE352268T1/de
Priority to EP99830721A priority patent/EP1103234B1/de
Priority to ES99830721T priority patent/ES2279610T3/es
Priority to DE69934990T priority patent/DE69934990T2/de
Priority to US09/692,373 priority patent/US6447439B1/en
Publication of EP1103234A1 publication Critical patent/EP1103234A1/de
Priority to US10/236,680 priority patent/US6585632B2/en
Application granted granted Critical
Publication of EP1103234B1 publication Critical patent/EP1103234B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1272—Sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1002—Intraluminal radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/92—Stents in the form of a rolled-up sheet expanding after insertion into the vessel, e.g. with a spiral shape in cross-section
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0095—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof radioactive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1002—Intraluminal radiation therapy
    • A61N2005/1004—Intraluminal radiation therapy having expandable radiation sources

Definitions

  • This invention relates to stents for angioplasty.
  • This name is intended to indicate in general devices which are intended for endoluminal application (e.g. within a blood vessel), normally fitted via catheterization, with subsequent deployment in situ so as to provide a local supporting effect for the lumen.
  • EP-A-0 806 190 EP-A-0 850 604, EP-A-0 847 766, EP-A-0 857 470, EP-A-0 875 215, EP-A-0 895 759 and EP-A-0 895 760.
  • phosphorus 32 has good characteristics in terms of half-life, it can be obtained with high specific activities and can be implanted on the surface of the stent, but has low penetration (14 days, 1.7 MeV beta radiation).
  • Palladium 103 has good half-life and penetration properties (17 days, 20 keV X-rays), but its specific activity is very low. Nevertheless the use of enriched palladium obtained by irradiation in a reactor or through cyclotron irradiation starting from rhodium and performing a chemical separation have been suggested. The main disadvantage of this arrangement is in the relatively high cost of the material so obtained.
  • Yttrium 90 has good penetration properties, but decays very quickly (64 hours, 2.2 MeV beta radiation). It has therefore been suggested that yttrium should be deposited on the stent a few hours before implantation, but this arrangement has appreciable problems and the possible effects in terms of biocompatibility have not yet been entirely clarified.
  • Ruthenium 106 has excellent properties in terms of penetration, but lasts too long (1 year, 3.5 MeV beta radiation).
  • radioisotopes such as silver 105
  • properties similar to palladium 103 have properties similar to palladium 103, and the same problems.
  • United States patents 5 722 984, 5 840 009 and 5 605 530 which refer to the application of substances such as phosphorylcholine labelled with phosphorus 32 to a stent, or means for overcoming the weakening of the dose at the ends of the stent through adding phosphorus 32 to the ends thereof, or again providing a screen to avoid the adverse effects of irradiation at the time when the stent is implanted.
  • United States patent 5 779 732 illustrates how a sheet of plastic containing a releasable substance can be located around a stent
  • EP-A-0 873 732 discloses a stent coated with a substance which attracts heparin to form a layer of heparin.
  • WO-A-98/48851 teaches how a radioisotope can be applied to a metal stent: a very great number of isotopes are considered and the stents are of steel or Nitinol. Methods of application are electrochemical, of the electrodeless type, using peptides, fats or thiols.
  • United States patents 5 865 720 and 5 840 008 teach how a type of radioactive sheath or sleeve can be placed around a balloon.
  • United States patent 5 707 332 examines in detail all possible radioisotopes which could be used for brachytherapy, but finds none to be ideal.
  • a source liquid or gas which is to be placed in the balloon, or a wire source which is moved forward and backwards in order to provide treatment as desired, is described.
  • the purpose of this invention is to provide an arrangement which is improved in comparison with the arrangements based on the local use of radioactive sources experimented with hitherto. This in particular as regards the function of countering restenosis.
  • this object can be achieved through a process having the features claimed in the claims below.
  • the invention also relates to a corresponding implantation kit.
  • the arrangement according to the invention offers a variety of advantages.
  • the device used to perform the process according to the invention can be applied to virtually any kind of stent, independently of e.g. the shape, type, technology of construction and method of expansion (balloon catheter, shape-memory, etc.) of the stent itself.
  • the device used to perform the process according to the invention can be constructed using a variety of techniques depending upon the radioactive agent delivered and/or the performance required: both the material or the constituent materials and the dimensions, and in particular the length, of the device are wholly independent - and may therefore also be markedly different - from the corresponding characteristics of the stent.
  • the envelope constituting the device may be made to be shorter (or longer) than the stent, if this corresponds to an application requirement.
  • the arrangement according to the invention therefore comprises making both the choice and the method of dosing the radioactive agent wholly independent of the characteristics of the stent.
  • the choice of radioactive agent can be optimized and/or different doses of radioactive agent can be used in different parts of the stent.
  • the arrangement according to the invention it is even possible to deliver several different radioactive agents to one stent, for example to achieve different radiation characteristics in different areas of the stent and/or at different times following implantation of the stent.
  • a basic feature is provided by the fact that the arrangement according to the invention makes it possible to activate only the radioactive agent which has been delivered (at most together with the means delivering it), thus avoiding it being necessary to activate the stent itself, even in part.
  • a first point of view is associated with the fact that the invention makes it possible to avoid activating the material comprising the stent.
  • activation of the stent as a whole gives rise to radiation phenomena which are difficult to control in relation to both dosage and the properties of the activated isotopes, and again in that it gives rise to mixed radiation resulting from various isotopes contained in the material forming the stent.
  • a second point of view is of a logistical nature: the device used to perform the process according to the invention is in fact associated with the stent only at the time of implantation and before such time may therefore follow a cycle of production, activation (usually by irradiation) and storage before and after activation which is wholly independent of the cycle for the production, distribution and storage of the stent.
  • the latter should not at any time be subjected to constraints imposed by the handling of radioactive material.
  • reference number 1 indicates a device used to perform the process according to the invention which is intended to be associated with an angioplasty stent in order to confer radioactive properties upon it.
  • this objective is pursued so as to associate an action countering restenosis with the stent.
  • the possible applications of the invention will not however be regarded as being restricted exclusively to this purpose.
  • the profile of the stent with which the device 1 is associated is indicated diagrammatically by reference S.
  • the stent is illustrated in the radially contracted condition and is shown essentially as a small tube of cylindrical shape.
  • stent S is a small tube having a diameter which is slightly less than and a length which is slightly greater than that of device 1.
  • both stent S and device 1 may have e.g. cross sections which vary along their longitudinal length, and therefore narrow portions, wide portions, parts having a cross section other than a circular cross section, etc.
  • Figures 1 to 12 refer provide that device 1 should be fitted on, that is, located outside stent S.
  • This arrangement which at the present time is regarded as being preferred (both because of the possibility that deployment and anchorage of device 1 at the site can be achieved automatically through the effect of the deployment of stent S, and because it is generally desired to encourage the radiation to act towards the walls of the vessel in which stent S is implanted), is not however mandatory.
  • the invention therefore also relates to embodiments in which device 1 is intended to be fitted within stent S, with suitable forms of radial anchorage being provided for this purpose.
  • Device 1 can therefore be taken from the corresponding protective container by the same person who is performing the implant, to be fitted over and "crimped" onto the stent immediately before the implanting operation.
  • the device 1 is in fact suitable for the preparation of implant kits comprising the stent S with associated device 1 (normally already activated), with the possibility of stent S being placed on the corresponding implantation catheter (of a known type).
  • Figures 1 to 12 will show how the device is designed to convey a material capable of exerting an effective radioactive effect at the site of the stent implant: this by being realised wholly or in part using such material or by delivering bodies comprising such material.
  • the radiation may be, e.g., X-rays having an energy of the order of 18-25 keV, which are not substantially attenuated in the first few millimetres of penetration.
  • Another advantageous choice is a high energy beta ray emitter such as yttrium 90.
  • a SR90/Y90 generator to produce a device 1 which is intended to be delivered to hospital within 1-2 days for use if appropriate in association with a corresponding stent in an implant kit.
  • the arrangement according to the invention is ideally suited to the possibility of coordinating the structure and construction technology of device 1 with the choice of radioactive material (it will be remembered that this material can in reality also comprise several radioactive isotopes), e.g. construction in the form of a wire or plate for use in combination with radioactive materials having ductility or malleability properties, or incorporation in a matrix in the presence of e.g. radioactive materials available in powder form.
  • radioactive material can in reality also comprise several radioactive isotopes, e.g. construction in the form of a wire or plate for use in combination with radioactive materials having ductility or malleability properties, or incorporation in a matrix in the presence of e.g. radioactive materials available in powder form.
  • Figures 1, 8 and 9 illustrate a possible example of device 1 used to perform the process according to the invention in the form of a tubular body (which on the whole can be likened to a stent in its structure) constructed from a wire-like material 10 itself comprising a material which is capable of being rendered radioactive. Also bearing in mind the quantity of material (10-20 mg) which is likely to be used to construct device 1, this may also be e.g. palladium, so that sufficient total activity can be provided without resorting to enriched palladium.
  • the wire-shaped material in question (which is capable of adopting the appearance of a plate, at least locally) is wound into a shape to give rise to a set of sections 11 of generally cylindrical shape in the form of a coil, connected together by lengths of wire 12 which extend in the direction of the generatrices of the cylindrical linear surface over which device 1 extends.
  • the corresponding manufacturing technology should be regarded as being well known, particularly in the field of stents: in this respect reference may be made to e.g. European patent application EP-A-0 806 190.
  • the device 1 may only be partly constructed of material which is capable of being made radioactive; for example, with reference to the example in Figure 1, in the form of wires of material which can be made radioactive woven or at least braided into a basic structure which is similar or related to that illustrated in Figure 1.
  • the variants in Figures 8 and 9 show that by acting on the structural features of device 1 it is possible to obtain a change in the density of the constituent material along the longitudinal length of the device, with a consequent possible variation in the radioactivity properties which can be achieved through the device 1.
  • Figure 8 relates to an example in which, while retaining the coil arrangement, the end sections 11' of device 1 are constructed having a sinusoidal shape with a smaller period (that is, figuratively speaking, a higher "frequency") in comparison with sections 11 which are located at the centre of device 1. All this has the effect that more material which is capable of being made radioactive is present in these end sections 11'.
  • the action of varying/modulating radioactive activity may also be achieved by different means, e.g. using different radio isotopes and/or different radioactivity properties in different portions of the stent.
  • the fact of increasing the level of local radioactivity at the ends of device 1 can be utilized for at least two purposes:
  • This latter example is advantageous when it is desired to counter the phenomena of restenosis which sometimes occur at the ends of the site where the stent is implanted, where the walls of the vessel are no longer supported and held apart by the stent itself.
  • Figure 9 shows a variant in which the two end sections, indicated by 11", are made of wire of different diameter (e.g. greater diameter) and/or different cross section (e.g. using a flattened transverse profile).
  • the two end sections are made of wire of different diameter (e.g. greater diameter) and/or different cross section (e.g. using a flattened transverse profile).
  • a symmetrical or asymmetrical arrangement is possible at the two ends of device 1 or, in general, in any region along the longitudinal extent of the means.
  • Figures 2 and 4 relate to examples which provide for producing device 1 in the form of a tubular body 13, e.g. of metal. This may then take the form of both a body which is already of a tubular shape (Figure 2) or a flat sheet which is curved and closed to form a tube using a longitudinal weld 13a ( Figure 3), or again a sheet which is merely wound on itself in accordance with a generally spiral arrangement (Figure 4).
  • the sheet may be capable of maintaining the closed configuration either through intrinsic plasticity properties (possibly associated with shape-memory properties) or because it is constrained by retaining members - not illustrated, but of a known type - whose action is reduced at the time when the stent on which the means are mounted is dilated.
  • the open structure which is necessary to ensure that device 1 follows the expansion movement of stent S is achieved by forming openings in the form of e.g. slots 14.
  • Manufacturing techniques laser cutting or EDM or chemical etching, etc. which can be applied to the construction of the devices in Figures 2 to 4 are in general known in the technology of stent manufacture and do not need to be illustrated specifically here.
  • the material which can be made radioactive may be a single well-defined isotope, a mixture of two or more isotopes intended to provide different radiation properties, or an alloy material containing one or more materials which are capable of being made radioactive among its components.
  • the variation in the type or types of the radioactive materials used makes it possible to achieve an effect modulating/varying the radiation characteristics in various sections or portions of the device, and therefore of the stent with which it is associated.
  • FIG. 5 to 7 and 10 are suitable for being used in a particularly advantageous form when the material which is capable of being rendered radioactive (again in this case a single isotope, a mixture of two or more isotopes, or a material which incorporates such an isotope or isotopes) is present in the form of particles, e.g. in the form of powder or micropowder. This is typically the situation for a material such as ruthenium.
  • device 1 may comprise a matrix 15 which is e.g. a small tube of extendable synthetic material (e.g. silicone) within which radioactive material 16 is dispersed.
  • matrix 15 is e.g. a small tube of extendable synthetic material (e.g. silicone) within which radioactive material 16 is dispersed.
  • Matrix material 15 may possibly have erodability/consumability properties such that it gives rise to slow release of material 16 (with consequent distancing from the site of implantation).
  • the dispersion of material 16 in the matrix may be uniform, as shown in Figure 5, or have the features of a differential density along the length of device 1, as shown in Figure 10.
  • the latter figure shows an example which in many respects is similar to those shown in Figures 8 and 9, that is a device in which the density of the distribution of radioactive material 16 in particle form is differentiated in such a way as to obtain a more marked local radioactive effect at the ends of device 1.
  • this result could also be achieved by acting on the type and the nature of material 16.
  • matrix 15 has a structure which is no longer compact, but apertured, for example of a reticular nature. This result may be obtained by starting from a compact tubular body, which is apertured for example by forming openings or notches (the rhomboidal shape of the mesh illustrated in Figure 6 is purely by way of example), or by weaving wires or fibres (e.g. of synthetic material such a silicone) in a general mesh structure.
  • a compact tubular body which is apertured for example by forming openings or notches (the rhomboidal shape of the mesh illustrated in Figure 6 is purely by way of example), or by weaving wires or fibres (e.g. of synthetic material such a silicone) in a general mesh structure.
  • the fibres in question may be fibres of the type described in patent application for an industrial invention TO 99A000693 (IT-A-1307263) bearing associated nanoparticles of materials which can be rendered radioactive, possibly with the properties of erodability.
  • Figure 7 shows a further possible variant which combines, so to speak, features from the example in Figure 5 (use of a matrix 15 in which material 16 which can be made radioactive is dispersed) with features of the example in Figure 4, in which device 1 is produced from a sheet wound into a coil.
  • the sheet forming matrix 15 should have extendibility properties.
  • material 16 dispersed in matrix 15 takes the form of wires, which may have different structural geometrical and/or composition properties in the various regions of means 1; in the example in Figure 12 the difference is illustrated by showing ends of wires indicated by 16' which have a different diameter/shape from the remainder of the wires.
  • the device in Figure 6 may be obtained by using metal wires which are even only partly coated with polymers or elastomers within which a material which can be made radioactive is dispersed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Radiation-Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Claims (42)

  1. Verfahren zum Übertragen von radioaktiven Mitteln auf einen Angioplastie-Stent (S), das die Schritte aufweist:
    - Bereitstellen einer Vorrichtung mit einer Hülle (1), die eine im wesentlichen rohrförmige Form aufweist und dazu geeignet ist, an dem Stent (S) angeordnet und durch den Effekt des Einsetzens des Stents (S) expandiert zu werden, wobei die Hülle (1) ein Material aufweist, das dazu geeignet ist, einen effektiven radioaktiven Effekt auszuüben,
    - Bereitstellen eines Angioplastie-Stents (S),
    - Behandeln des Materials derart, dass es radioaktiv effektiv ist, und
    - Anordnen der Hülle (1) an dem Stent (S) mit dem Ziel, den Stent (S) zu implantieren, wobei die Hülle (1) an dem Ort radioaktiv gemacht wird, an dem der Stent (S) implantiert wird.
  2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass das Material radioaktiv effektiv gemacht wird, bevor die Hülle (1) an dem Stent (S) angeordnet wird.
  3. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass das Material radioaktiv effektiv gemacht wird, nachdem die Hülle (1) an dem Stent (S) angeordnet wurde.
  4. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass das Material ungleichmäßig (11', 11 " , 16') innerhalb der Umgebung der Hülle (1) verteilt ist.
  5. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Hülle (1) eine Drahtstruktur (11, 12) aufweist.
  6. Verfahren nach Anspruch 5, dadurch gekennzeichnet, dass der Draht ungleichmäßige Eigenschaften innerhalb der Umgebung der Hülle (1) aufweist.
  7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, dass der Draht unterschiedliche Wickeleigenschaften (11') in verschiedenen Bereichen der Hülle (1) aufweist.
  8. Verfahren nach Anspruch 6, dadurch gekennzeichnet, dass der Draht einen Durchmesser und/oder Formeigenschaften (11") aufweist, die sich innerhalb der Umgebung der Hülle (1) unterscheiden.
  9. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Hülle einen flachen Körper (13) aufweist, der zu einer rohrförmigen Form mit Hilfe einer Schweißnaht (13a) verschlossen ist.
  10. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Hülle einen blechartigen Körper (13) aufweist, der zu einer Spirale gewickelt ist.
  11. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Hülle (1) eine im wesentlichen offene Struktur (14; 16) aufweist.
  12. Verfahren nach Anspruch 11, dadurch gekennzeichnet, dass die Hülle (1) eine insgesamt netzförmige Struktur (16) aufweist.
  13. Verfahren nach einem der Ansprüche 11 oder 12, dadurch gekennzeichnet, dass die Hülle (1) ein im wesentlichen nicht-dehnbares Material aufweist.
  14. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Anordnungsoperation durchgeführt wird, um die Hülle (1) über der Außenseite des Stents (S) anzuordnen.
  15. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass das Material eine einzelne Komponente aufweist, die dazu geeignet ist, einen radioaktiven Effekt auszuüben.
  16. Verfahren nach einem der Ansprüche 1 bis 14, dadurch gekennzeichnet, dass das Material mehrere Komponenten aufweist, die dazu geeignet sind, entsprechende radioaktive Effekte auszuüben.
  17. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Hülle (1) vollständig (11, 12, 13) aus dem Material besteht, das dazu geeignet ist, einen radioaktiven Effekt zu bewirken.
  18. Verfahren nach einem der Ansprüche 1 bis 16, dadurch gekennzeichnet, dass die Hülle teilweise das Material (16) aufweist, das dazu geeignet ist, einen radioaktiven Effekt auszuüben.
  19. Verfahren nach Anspruch 16, dadurch gekennzeichnet, dass die Hülle (1) eine Matrix (15) umfasst, in die das Material, das dazu geeignet ist, einen radioaktiven Effekt auszuüben, in einer Partikel- und/oder Drahtform (16) zugeführt wird.
  20. Verfahren nach Anspruch 19, dadurch gekennzeichnet, dass das Material, das dazu geeignet ist, einen radioaktiven Effekt auszuüben, ungleichmäßig innerhalb der Matrix (15) zugeführt wird.
  21. Verfahren nach Anspruch 19 oder 20, dadurch gekennzeichnet, dass die Matrix (15) in der Form von Fasern vorgesehen ist.
  22. Verfahren nach einem der Ansprüche 18 bis 21, dadurch gekennzeichnet, dass das Material (16), das dazu geeignet ist, einen radioaktiven Effekt zu bewirken, wenigstens teilweise in der Form von Nanopartikeln vorhanden ist.
  23. Verfahren nach einem der Ansprüche 19 bis 22, dadurch gekennzeichnet, dass die Matrix (15) Erosions/Verbrauchs-Eigenschaften aufweist, um ein allmähliches Lösen des Materials (16) zuzulassen.
  24. Angioplastie-Stent-Implantationssatz, der aufweist:
    - einen Angioplastie-Stent (S) und
    - eine Vorrichtung mit einer Hülle (1), die eine im wesentlichen rohrförmige Form aufweist und dazu geeignet ist, an dem Stent (S) angeordnet zu werden und sich durch die Wirkung des Einsetzens des Stents (S) zu expandieren, wobei die Hülle (1) ein Material umfasst, das dazu geeignet ist, einen effektiven radioaktiven Effekt zu bewirken, und das Material radioaktiv effektiv gemacht wird.
  25. Satz nach Anspruch 24, dadurch gekennzeichnet, dass das Material ungleichmäßig (11', 11", 16') innerhalb der Umgebung der Hülle (1) verteilt ist.
  26. Satz nach Anspruch 24, dadurch gekennzeichnet, dass die Hülle (1) eine Drahtstruktur (11, 12) aufweist.
  27. Satz nach Anspruch 26, dadurch gekennzeichnet, dass der Draht ungleichmäßige Eigenschaften innerhalb der Umgebung der Hülle (1) aufweist.
  28. Satz nach Anspruch 27, dadurch gekennzeichnet, dass der Draht verschiedene Wickeleigenschaften (11') in verschiedenen Bereichen der Hülle (1) aufweist.
  29. Satz nach Anspruch 24, dadurch gekennzeichnet, dass die Hülle (1) einen flachen Körper (13) aufweist, der zu einer rohrförmigen Form mit Hilfe einer Schweißnaht (13a) verschlossen ist.
  30. Satz nach Anspruch 24, dadurch gekennzeichnet, dass die Hülle einen blechartigen Körper (13) aufweist, der zu einer Spirale gewickelt ist.
  31. Satz nach einem der Ansprüche 24 bis 30, dadurch gekennzeichnet, dass die Hülle eine im wesentlichen offene Struktur (14; 16) aufweist.
  32. Satz nach Anspruch 24, dadurch gekennzeichnet, dass die Hülle (1) eine insgesamt netzförmige Struktur (16) aufweist.
  33. Satz nach einem der Ansprüche 24 bis 32, dadurch gekennzeichnet, dass die Hülle (1) dazu geeignet ist, über der Außenseite des Stents (S) angeordnet zu werden.
  34. Satz nach einem der Ansprüche 24 bis 33, dadurch gekennzeichnet, dass das Material eine einzelne Komponente umfasst, die dazu geeignet ist, einen radioaktiven Effekt auszuüben.
  35. Satz nach einem der Ansprüche 24 bis 33, dadurch gekennzeichnet, dass das Material mehrere Komponenten aufweist, die dazu geeignet sind, entsprechende radioaktive Effekte auszuüben.
  36. Satz nach einem der Ansprüche 24 bis 35, dadurch gekennzeichnet, dass die Hülle (1) vollständig (11, 12, 13) aus dem Material besteht, das dazu geeignet ist, einen radioaktiven Effekt zu bewirken.
  37. Satz nach einem der Ansprüche 24 bis 35, dadurch gekennzeichnet, dass die Hülle (1) nur teilweise das Material (16) umfasst, das dazu geeignet ist, einen radioaktiven Effekt zu bewirken.
  38. Satz nach Anspruch 35, dadurch gekennzeichnet, dass die Hülle (1) eine Matrix (15) umfasst, in die das Material (16), das dazu geeignet ist, einen radioaktiven Effekt zu bewirken, in einer Partikel- und/oder Drahtform zugeführt wird.
  39. Satz nach Anspruch 38, dadurch gekennzeichnet, dass das Material (16), das dazu geeignet ist, einen radioaktiven Effekt zu bewirken, ungleichmäßig der Matrix (15) zugeführt wird.
  40. Satz nach Anspruch 38 oder 39, dadurch gekennzeichnet, dass die Matrix (15) in der Form von Fasern vorgesehen ist.
  41. Satz nach einem der Ansprüche 37 bis 40, dadurch gekennzeichnet, dass das Material (16), das dazu geeignet ist, einen radioaktiven Effekt zu bewirken, wenigstens teilweise in der Form von Nanopartikeln vorhanden ist.
  42. Satz nach einem der Ansprüche 38 bis 41, dadurch gekennzeichnet, dass die Matrix (15) Erosions/Verbrauchs-Eigenschaften aufweist, so dass das Material (16) allmählich freigesetzt werden kann.
EP99830721A 1999-11-23 1999-11-23 Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz Expired - Lifetime EP1103234B1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT99830721T ATE352268T1 (de) 1999-11-23 1999-11-23 Verfahren zur übertragung radioaktiver stoffe auf stents in der angioplastie und bausatz
EP99830721A EP1103234B1 (de) 1999-11-23 1999-11-23 Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz
ES99830721T ES2279610T3 (es) 1999-11-23 1999-11-23 Dispositivo para transferir agentes radioactivos sobre stents de angioplastia y kit respectivo.
DE69934990T DE69934990T2 (de) 1999-11-23 1999-11-23 Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz
US09/692,373 US6447439B1 (en) 1999-11-23 2000-10-19 Device for conveying radioactive agents on angioplasty stents, respective method and kit
US10/236,680 US6585632B2 (en) 1999-11-23 2002-09-06 Device for conveying radioactive agents on angioplasty stents, respective method and kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99830721A EP1103234B1 (de) 1999-11-23 1999-11-23 Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz

Publications (2)

Publication Number Publication Date
EP1103234A1 EP1103234A1 (de) 2001-05-30
EP1103234B1 true EP1103234B1 (de) 2007-01-24

Family

ID=8243677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99830721A Expired - Lifetime EP1103234B1 (de) 1999-11-23 1999-11-23 Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz

Country Status (5)

Country Link
US (2) US6447439B1 (de)
EP (1) EP1103234B1 (de)
AT (1) ATE352268T1 (de)
DE (1) DE69934990T2 (de)
ES (1) ES2279610T3 (de)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169173B2 (en) 2001-06-29 2007-01-30 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material and a method of forming the same
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7258891B2 (en) 2001-06-28 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US7297159B2 (en) 2000-10-26 2007-11-20 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US7563324B1 (en) 2003-12-29 2009-07-21 Advanced Cardiovascular Systems Inc. System and method for coating an implantable medical device
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US7674493B2 (en) 2001-04-12 2010-03-09 Advanced Cardiovascular Systems, Inc. Method of making a variable surface area stent
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
US20090000007A1 (en) * 1998-12-07 2009-01-01 Meridian Research And Development, Inc. Nonwoven radiopaque material for medical garments and method for making same
US7476889B2 (en) * 1998-12-07 2009-01-13 Meridian Research And Development Radiation detectable and protective articles
DE69934990T2 (de) * 1999-11-23 2007-11-15 Sorin Biomedica Cardio S.R.L., Saluggia Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz
US6379382B1 (en) * 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
AU7528101A (en) * 2000-06-05 2001-12-17 Theragenics Corp A device for delivering a therapeutic dosage
US7232460B2 (en) * 2001-04-25 2007-06-19 Xillus, Inc. Nanodevices, microdevices and sensors on in-vivo structures and method for the same
ES2266148T5 (es) 2001-07-20 2012-11-06 Sorin Biomedica Cardio S.R.L. Stent
JP2005503865A (ja) * 2001-09-28 2005-02-10 ボストン サイエンティフィック リミテッド ナノ材料からなる医療デバイス及びそれを利用した治療方法
US7291165B2 (en) 2002-01-31 2007-11-06 Boston Scientific Scimed, Inc. Medical device for delivering biologically active material
US7326245B2 (en) 2002-01-31 2008-02-05 Boston Scientific Scimed, Inc. Medical device for delivering biologically active material
US7445629B2 (en) 2002-01-31 2008-11-04 Boston Scientific Scimed, Inc. Medical device for delivering biologically active material
JP2006500997A (ja) * 2002-09-27 2006-01-12 メドロジックス デバイス コーポレイション 端部を改変された移植可能なステント
EP1449546B1 (de) 2003-02-21 2010-10-27 Sorin Biomedica Cardio S.R.L. Verfahren zur Herstellung eines Stents und entsprechender Stent
ITTO20040056A1 (it) 2004-02-05 2004-05-05 Sorin Biomedica Cardio Spa Stent per l'erogazione endoliminale di principi o agenti attivi
US20070073387A1 (en) * 2004-02-27 2007-03-29 Forster David C Prosthetic Heart Valves, Support Structures And Systems And Methods For Implanting The Same
US8128692B2 (en) 2004-02-27 2012-03-06 Aortx, Inc. Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same
US20090132035A1 (en) * 2004-02-27 2009-05-21 Roth Alex T Prosthetic Heart Valves, Support Structures and Systems and Methods for Implanting the Same
KR100731278B1 (ko) * 2005-01-31 2007-06-25 주식회사 와이어리스데이터커뮤니케이션 안테나 어셈블리
US8834338B2 (en) * 2005-02-10 2014-09-16 Snip Holdings, Inc. Dosimetry implant for treating restenosis and hyperplasia
US8403981B2 (en) 2006-02-27 2013-03-26 CardiacMC, Inc. Methods and devices for delivery of prosthetic heart valves and other prosthetics
US8147541B2 (en) 2006-02-27 2012-04-03 Aortx, Inc. Methods and devices for delivery of prosthetic heart valves and other prosthetics
EP1834606B1 (de) 2006-03-16 2013-04-24 CID S.p.A. Stents
US8585594B2 (en) 2006-05-24 2013-11-19 Phoenix Biomedical, Inc. Methods of assessing inner surfaces of body lumens or organs
CN101506538A (zh) * 2006-06-20 2009-08-12 奥尔特克斯公司 扭矩轴和扭矩驱动
WO2007149910A2 (en) 2006-06-20 2007-12-27 Aortx, Inc. Prosthetic heart valves, support structures and systems and methods for implanting the same
EP2068727A4 (de) * 2006-06-20 2012-12-19 Aortx Inc Verfahren zur vorbereitung einer stelle zur implantierung einer klappenprothese
AU2007260951A1 (en) 2006-06-21 2007-12-27 Aortx, Inc. Prosthetic valve implantation systems
EP2063807A4 (de) * 2006-09-06 2010-03-31 Aortx Inc Herzklappenprothesen, stützstrukturen und systeme und verfahren zu ihrer implantation
US8257304B2 (en) * 2007-06-01 2012-09-04 Tyco Healthcare Group Lp Extension tubes for balloon catheters
US20090163919A1 (en) * 2007-12-19 2009-06-25 Peter Tarcha Devices, systems, and methods for delivery of a pharmaceutical to a subject's spine
EP2338534A2 (de) * 2009-12-21 2011-06-29 Biotronik VI Patent AG Medizinisches Implantat, Beschichtungsverfahren sowie Implantationsverfahren
US9332990B2 (en) * 2010-12-30 2016-05-10 Wake Forest University Health Sciences Ureter to ileal conduit anastomosis using magnetic compression and related delivery devices and methods
IT201900003579A1 (it) 2019-03-12 2020-09-12 Alvimedica Tibbi Ueruenler Sanayi Ve Dis Ticaret A S Stent per ostio coronarico

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
WO1995029647A2 (en) * 1994-04-29 1995-11-09 Scimed Life Systems, Inc. Stent with collagen

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349498A (en) 1981-01-16 1982-09-14 Carbomedics, Inc. Radio-opaque markers for pyrolytic carbon prosthetic members
US4503569A (en) 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
EP0556940A1 (de) 1986-02-24 1993-08-25 Robert E. Fischell Intravaskulärer Stent
US4819618A (en) 1986-08-18 1989-04-11 Liprie Sam F Iridium/platinum implant, method of encapsulation, and method of implantation
US4907336A (en) 1987-03-13 1990-03-13 Cook Incorporated Method of making an endovascular stent and delivery system
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4830003A (en) 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US4856516A (en) 1989-01-09 1989-08-15 Cordis Corporation Endovascular stent apparatus and method
US5176617A (en) 1989-12-11 1993-01-05 Medical Innovative Technologies R & D Limited Partnership Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5059166A (en) 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5342283A (en) 1990-08-13 1994-08-30 Good Roger R Endocurietherapy
US5213561A (en) 1990-09-06 1993-05-25 Weinstein Joseph S Method and devices for preventing restenosis after angioplasty
US5395300A (en) 1991-06-07 1995-03-07 Omnitron International, Inc. High dosage radioactive source
US5500013A (en) 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
CA2079417C (en) 1991-10-28 2003-01-07 Lilip Lau Expandable stents and method of making same
US5383928A (en) 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
DE69326455T2 (de) * 1993-07-01 2000-01-20 Schneider (Europe) Gmbh, Buelach Arzneigeräte für die Behandlung von Blutgefässen mittels ionisierungsbestrahlung
EP0662806B1 (de) 1993-07-23 2001-04-11 Cook Incorporated Flexibler stent mit einer aus einem materialbogen geformten konfiguration
US5707332A (en) 1994-01-21 1998-01-13 The Trustees Of Columbia University In The City Of New York Apparatus and method to reduce restenosis after arterial intervention
US5449373A (en) 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
US5733303A (en) 1994-03-17 1998-03-31 Medinol Ltd. Flexible expandable stent
ES2235174T3 (es) 1994-10-17 2005-07-01 Kabushikikaisha Igaki Iryo Sekkei Stent liberador de medicamento.
US5707385A (en) 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
WO1996022121A1 (de) 1995-01-17 1996-07-25 Christoph Hehrlein Ballon-katheter zur verhinderung der re-stenose nach angioplastie, und verfahren zum herstellen eines ballon-katheters
US5575818A (en) * 1995-02-14 1996-11-19 Corvita Corporation Endovascular stent with locking ring
US5605530A (en) 1995-03-23 1997-02-25 Fischell; Robert E. System for safe implantation of radioisotope stents
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US5840008A (en) 1995-11-13 1998-11-24 Localmed, Inc. Radiation emitting sleeve catheter and methods
US5840009A (en) * 1995-12-05 1998-11-24 Isostent, Inc. Radioisotope stent with increased radiation field strength at the ends of the stent
EP0871413B1 (de) * 1995-12-11 2001-08-22 Ali Hassan Einrichtung zum stabilisieren von angioplastisch behandelten teilbereichen einer gefässwand (stent)
US5722984A (en) 1996-01-16 1998-03-03 Iso Stent, Inc. Antithrombogenic radioactive coating for an intravascular stent
BR9708046A (pt) * 1996-03-11 2000-01-04 Focal Inc Método para radioterapia local nim paciente e respectiva composição.
CA2199890C (en) * 1996-03-26 2002-02-05 Leonard Pinchuk Stents and stent-grafts having enhanced hoop strength and methods of making the same
ES2212013T3 (es) 1996-05-08 2004-07-16 Sorin Biomedica Cardio S.P.A. Stent de angioplastia.
US5843163A (en) 1996-06-06 1998-12-01 Wall; William H. Expandable stent having radioactive treatment means
US5871436A (en) 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
US5871437A (en) 1996-12-10 1999-02-16 Inflow Dynamics, Inc. Radioactive stent for treating blood vessels to prevent restenosis
IT1289728B1 (it) 1996-12-10 1998-10-16 Sorin Biomedica Cardio Spa Dispositivo di impianto e corredo che lo comprende
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
IT1291001B1 (it) 1997-01-09 1998-12-14 Sorin Biomedica Cardio Spa Stent per angioplastica e suo procedimento di produzione
US5873811A (en) 1997-01-10 1999-02-23 Sci-Med Life Systems Composition containing a radioactive component for treatment of vessel wall
US5865720A (en) 1997-03-06 1999-02-02 Scimed Life Systems, Inc. Expandable and retrievable radiation delivery system
US5779732A (en) 1997-03-31 1998-07-14 Medtronic, Inc. Method and apparatus for implanting a film with an exandable stent
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
IT1292295B1 (it) 1997-04-29 1999-01-29 Sorin Biomedica Cardio Spa Stent per angioplastica
DE19724230C1 (de) 1997-04-30 1998-11-26 Schering Ag Radioaktiv beschichtete Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US5919126A (en) 1997-07-07 1999-07-06 Implant Sciences Corporation Coronary stent with a radioactive, radiopaque coating
EP0998309A1 (de) * 1997-07-11 2000-05-10 Innerdyne Medical, Inc. Verfahren und vorrichtungen zur vorbereitung und dichtung von strahlentherapie-strukturen
US5919163A (en) * 1997-07-14 1999-07-06 Delcath Systems, Inc. Catheter with slidable balloon
IT1293691B1 (it) 1997-08-08 1999-03-08 Sorin Biomedica Cardio Spa Stent per angioplastica, particolarmente per il trattamento di vasi presentanti biforcazioni.
IT1293690B1 (it) 1997-08-08 1999-03-08 Sorin Biomedica Cardio Spa Stent per angioplastica, particolarmente per il trattamento di lesioni aorto-ostiali ed ostiali.
US6013099A (en) 1998-04-29 2000-01-11 Medtronic, Inc. Medical device for delivering a water-insoluble therapeutic salt or substance
US6129757A (en) 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
US6149575A (en) * 1998-07-07 2000-11-21 World Medical Manufacturing Corporation Radiation delivery catheter
CA2338788A1 (en) 1998-09-02 2000-03-09 Scimed Life Systems, Inc. Drug delivery device for stent
DE69934990T2 (de) * 1999-11-23 2007-11-15 Sorin Biomedica Cardio S.R.L., Saluggia Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz
US6379382B1 (en) * 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
WO1995029647A2 (en) * 1994-04-29 1995-11-09 Scimed Life Systems, Inc. Stent with collagen

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297159B2 (en) 2000-10-26 2007-11-20 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
US7674493B2 (en) 2001-04-12 2010-03-09 Advanced Cardiovascular Systems, Inc. Method of making a variable surface area stent
US8119184B2 (en) 2001-04-12 2012-02-21 Advanced Cardiovascular Systems, Inc. Method of making a variable surface area stent
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US7258891B2 (en) 2001-06-28 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US7169173B2 (en) 2001-06-29 2007-01-30 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material and a method of forming the same
US8025916B2 (en) 2001-06-29 2011-09-27 Abbott Cardiovascular Systems Inc. Methods for forming a composite stent with regioselective material
US8961584B2 (en) 2001-06-29 2015-02-24 Abbott Cardiovascular Systems Inc. Composite stent with regioselective material
US7824441B2 (en) 2002-11-12 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US7666223B2 (en) 2002-11-12 2010-02-23 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US7820229B2 (en) 2002-11-12 2010-10-26 Advanced Cardiovascular Systems, Inc. Method of coating a stent
US7824440B2 (en) 2002-11-12 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US8197879B2 (en) 2003-09-30 2012-06-12 Advanced Cardiovascular Systems, Inc. Method for selectively coating surfaces of a stent
US7604700B2 (en) 2003-09-30 2009-10-20 Advanced Cardiovascular Systems, Inc. Stent mandrel fixture and method for selectively coating surfaces of a stent
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7563324B1 (en) 2003-12-29 2009-07-21 Advanced Cardiovascular Systems Inc. System and method for coating an implantable medical device
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8465789B2 (en) 2006-05-04 2013-06-18 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8596215B2 (en) 2006-05-04 2013-12-03 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8637110B2 (en) 2006-05-04 2014-01-28 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8741379B2 (en) 2006-05-04 2014-06-03 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8808342B2 (en) 2006-06-14 2014-08-19 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8293367B2 (en) 2006-06-23 2012-10-23 Advanced Cardiovascular Systems, Inc. Nanoshells on polymers
US8592036B2 (en) 2006-06-23 2013-11-26 Abbott Cardiovascular Systems Inc. Nanoshells on polymers
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices

Also Published As

Publication number Publication date
US20030009076A1 (en) 2003-01-09
DE69934990D1 (de) 2007-03-15
ES2279610T3 (es) 2007-08-16
EP1103234A1 (de) 2001-05-30
ATE352268T1 (de) 2007-02-15
US6585632B2 (en) 2003-07-01
DE69934990T2 (de) 2007-11-15
US6447439B1 (en) 2002-09-10

Similar Documents

Publication Publication Date Title
EP1103234B1 (de) Verfahren zur Übertragung radioaktiver Stoffe auf Stents in der Angioplastie und Bausatz
US6187037B1 (en) Metal stent containing radioactivatable isotope and method of making same
ES2268740T3 (es) Procedimiento de produccion de un stent para angioplastia.
US6010445A (en) Radioactive medical device and process
EP0433011B1 (de) Intraarterielle Stützeinrichtung mit der Fähigkeit der Hemmung einer Intimahyperplasie
US6192271B1 (en) Radiotherapy stent
US6261320B1 (en) Radioactive vascular liner
US6699170B1 (en) Radiation delivery balloon catheter
EP0805703B1 (de) Ballon-katheter zur verhinderung der re-stenose nach angioplastie, und verfahren zum herstellen eines ballon-katheters
US6491619B1 (en) Radiation delivery catheters and dosimetry methods
EP0539165A1 (de) Gallengangstent
US20080009938A1 (en) Stent with a radiopaque marker and method for making the same
JP2002502638A (ja) 軟ｘ線を放射する医療器具
JPH08508436A (ja) 血管植込み物
US20060178736A1 (en) Stent for neutron capture therapy and method of manufacture therefor
JP2002503533A (ja) 放射性ステント
US20030149329A1 (en) Formable integral source material for medical devices
US6770019B1 (en) Radiation source for endovascular radiation treatment in form of a wire
JP2003518392A (ja) 植え込み型医療用デバイスの製造に適した放射化可能組成物
WO2001021106A9 (en) Radioactive graft or cuff

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20011017

AKX Designation fees paid

Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

17Q First examination report despatched

Effective date: 20040517

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SORIN BIOMEDICA CARDIO S.R.L.

RTI1 Title (correction)

Free format text: METHOD FOR CONVEYING RADIOACTIVE AGENTS ON ANGIOPLASTY STENTS AND KIT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070124

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070124

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69934990

Country of ref document: DE

Date of ref document: 20070315

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070400977

Country of ref document: GR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070625

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2279610

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20071025

BERE Be: lapsed

Owner name: SORIN BIOMEDICA CARDIO S.R.L.

Effective date: 20071130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071130

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20080601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071124

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080601

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071123

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070425

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20071124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20101113

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 69934990

Country of ref document: DE

Representative=s name: PAUL & ALBRECHT PATENTANWALTSSOZIETAET, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 69934990

Country of ref document: DE

Representative=s name: PAUL & ALBRECHT PATENTANWALTSSOZIETAET, DE

Effective date: 20130108

Ref country code: DE

Ref legal event code: R081

Ref document number: 69934990

Country of ref document: DE

Owner name: CID S.P.A., SALUGGIA, IT

Free format text: FORMER OWNER: SORIN BIOMEDICA CARDIO S.R.L., SALUGGIA, VERCELLI, IT

Effective date: 20130108

Ref country code: DE

Ref legal event code: R081

Ref document number: 69934990

Country of ref document: DE

Owner name: CID S.P.A., IT

Free format text: FORMER OWNER: SORIN BIOMEDICA CARDIO S.R.L., SALUGGIA, VERCELLI, IT

Effective date: 20130108

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: CID S.P.A., IT

Effective date: 20130228

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20130627 AND 20130703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121123

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181113

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20181011

Year of fee payment: 20

Ref country code: GB

Payment date: 20181121

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69934990

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20191122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191122